Long-term follow-up of Wilson disease: natural history, treatment, mutations analysis and phenotypic correlation
Language English Country United States Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Adenosine Triphosphatases genetics metabolism MeSH
- Asymptomatic Diseases MeSH
- Copper-Transporting ATPases MeSH
- Time Factors MeSH
- Chelating Agents metabolism MeSH
- Adult MeSH
- Phenotype MeSH
- Gene Frequency MeSH
- Genetic Predisposition to Disease MeSH
- Hepatolenticular Degeneration enzymology genetics mortality therapy MeSH
- Kaplan-Meier Estimate MeSH
- Middle Aged MeSH
- Humans MeSH
- Copper metabolism MeSH
- Adolescent MeSH
- Young Adult MeSH
- Mutation * MeSH
- DNA Mutational Analysis MeSH
- Zinc Acetate therapeutic use MeSH
- Penicillamine therapeutic use MeSH
- Disease Progression MeSH
- Cation Transport Proteins genetics metabolism MeSH
- Retrospective Studies MeSH
- Chi-Square Distribution MeSH
- Zinc Sulfate therapeutic use MeSH
- Liver Transplantation MeSH
- Treatment Outcome MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Adolescent MeSH
- Young Adult MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Geographicals
- Czech Republic MeSH
- Names of Substances
- Adenosine Triphosphatases MeSH
- ATP7B protein, human MeSH Browser
- Copper-Transporting ATPases MeSH
- Chelating Agents MeSH
- Copper MeSH
- Zinc Acetate MeSH
- Penicillamine MeSH
- Cation Transport Proteins MeSH
- Zinc Sulfate MeSH
BACKGROUND AND AIMS: Wilson disease (WD) is an inherited disorder of copper metabolism. When treated, the outcome can be excellent, although the long-term survival has yet to be well documented. The aim of this study was to describe the long-term outcome of a cohort of patients with WD and to assess those factors affecting the phenotypic manifestation of WD. METHODS: The presence of mutations to the ATP7B gene, the clinical manifestations, treatments and the long-term outcomes were analysed retrospectively in 117 patients with WD (59 men and 58 women, aged at evaluation 38.5 ± 11, range 16-63 years). RESULTS: Fifty-five patients with a neurological presentation, 51 patients with a hepatic presentation and 11 asymptomatic patients were followed up for an average of 15.1 ± 10 years (median 12 years, range 1-41 years). The H1069Q ATP7B gene mutation was the most frequent genetic variant (54.3%); the frequency of this mutation did not differ between patients with either the hepatic or the neurological presentation (P = 0.099). d-penicillamine or zinc salts (81 and 17% respectively) were used for treatment, and three patients underwent liver transplantation. The majority of symptomatic patients became asymptomatic, or improved, during the follow-up (82% patients with hepatic presentation, 69% with neurological presentation). The long-term survival of patients with WD did not differ from that of the general Czech population (P = 0.95). CONCLUSIONS: Long-term follow-up shows a satisfactory response in the great majority of adequately treated patients with WD and survival coincides with that of the general population.
References provided by Crossref.org
Psychiatric manifestations in Wilson's disease: possibilities and difficulties for treatment